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Background: Not only four but rather seven different human epidermal growth factor receptor related (Her)
receptor tyrosine kinases (RTKs) have been described to be expressed in a variety of normal and neoplastic tissues:
Her1, Her2, Her3, and additionally four Her4 isoforms have been identified. A differential expression of Her4 isoforms
does not, however, play any role in either the molecular diagnostics or treatment decision for breast cancer
patients. The prognostic and predictive impact of Her4 expression in breast cancer is basically unclear.
Methods: We quantified the Her4 variants JM-a/CYT1, JM-a/CYT2, JM-b/CYT1, and JM-b/CYT2 by isoform-specific
polymerase chain reaction (qPCR) in (i) triple-negative, (ii) Her2 positive breast cancer tissues and (iii) in benign
breast tissues.
Results: In all three tissue collectives we never found the JM-b/CYT1 or the JM-b/CYT2 isoform expressed. In
contrast, the two JM-a/CYT1 and JM-a/CYT2 isoforms were always simultaneously expressed but at different ratios.
We identified a positive prognostic impact on overall survival (OS) in triple-negative and event-free survival (EFS) in
Her2 positive patients. This finding is independent of the absolute JM-a/CYT1 to JM-a/CYT2 expression ratio. In
Her2 positive patients, Her4 expression only has a favorable effect in estrogen-receptor (ER)-positive but not in
ER-negative individuals.
Conclusion: In summary, JM-a/CYT1 and JM-a/CYT2 but not JM-b isoforms of the Her4 receptor are simultaneously
expressed in both triple-negative and Her2 positive breast cancer tissues. Although different expression ratios of
the two JM-a isoforms did not reveal any additional information, Her4 expression basically indicates a prolonged
EFS and OFS. An extended expression analysis that takes all Her receptor homologs, including the Her4 isoforms,
into account might render more precisely the molecular diagnostics required for the development of optimized
targeted therapies.
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The Her (human epidermal growth factor related) recep-
tor tyrosine kinases (RTK) comprise four homologous
proteins (Her1-4), which are differentially expressed dur-
ing development and functional maintenance of the nor-
mal mammary gland [1-4]. Spatiotemporally regulated
RTK (co-)expression, however, is commonly disturbed in* Correspondence: gero.brockhoff@ukr.de
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reproduction in any medium, provided the orneoplastic mammary epithelium. 15% - 25% of breast
cancers show Her2 receptor overexpression, which has a
negative prognostic impact on the outcome of disease
[5]. Specific Her2 receptor targeting with antibodies (e.g.
trastuzumab and/or pertuzumab) or small molecule
kinase inhibitors (e.g. lapatinib), usually applied in com-
bination with chemotherapy or antihormonal therapeutic
intervention, potentially prolongs the time to tumor pro-
gression and/or the overall survival rate of palliatively
(metastatic) or (neo-)adjuvantly treated breast cancer
patients [6]. Individual responsiveness, however, (based onral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic TNBC and Her2 positive patient
characteristics
TNBC Her2 positive
# Total 76 (100%) 96 (100%)
Median
patient age
54.3 y (range 28 – 83) 54.0 (range 24 – 79)
# Grading 1 1 (1.3%) 0 (0%)
# Grading 2 20 (26.3%) 39 (40.6%)
# Grading 3 54 (71.1%) 56 (58.3%)
# Grading
unknown
1 (1.3%) 1 (1.0%)
# Stage 1 17 (22.4%) 17 (17.7%)
# Stage 2 41 (53.9%) 42 (43.8%)
# Stage 3 9 (11.8%) 22 (22.9%)
# Stage 4 4 (5.3%) 13 (13.5%)
# Staging
unknown
5 (6.6%) 2 (2.1%)
pNO
(initial diagnosis)
41 (53.9%) 33 (34.3%)
pN+ 29 (38.2%) 58 (60.4%)
pNX 6 (7.9%) 5 (5.2%)
Metastatic patients
(initial diagnosis)
14 (18.4%) 13 (13.5%)
Median OS [months] 55.8 (range 0.9 – 238) 41.2 (range 13.0 – 193.5)
Median EFS [months] 50.9 (range 0.9 – 197.9) 33.3 (range 7.8 – 114)
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be predicted, varies significantly, and spans from de-
novo to acquired resistance to moderate and high
susceptibility [7].
Her1 and Her3 receptor expression in breast cancer
has been described to be associated with a poor course
and outcome of disease [8,9]. In contrast, the prognostic
(and predictive) value of Her4 receptor expression is
uncertain [10-16]. Both a positive and a negative impact
of Her4 (co-)expression has been reported. This incon-
sistency can be conceivably attributed to the complex
Her4 signaling capabilities, which among other reasons,
might result from the differential expression of alterna-
tively spliced Her4 isoforms [17,18]. In fact, at least four
different Her4 variants (JM-a/CYT1, JM-a/CYT2, JM-b/
CYT1, and JM-b/CYT2) can be generated by differential
Her4 mRNA splicing. The juxtamembrane domain JM-a,
but not JM-b, contains a cleavage site for the tumor-
necrosis-factor-α-converting enzyme (TACE). CYT1/CYT2
intracellular domains have been demonstrated to diffe-
rentially trigger intracellular signaling upon further Her4
activation by γ-secretase [19,20]. Hence, the Her4 types
differ in both function and signaling capabilities. Overall,
not only four different Her receptors (Her1-4) but rather
seven homologs (Her1-3 plus four Her4 isoforms) can
potentially be coexpressed [17]. The prognostic value of
isoform-related Her4 expression in breast cancer is,
however, unknown.
The aim of this study was to evaluate the prognostic
impact of Her4 isoform expression in well-characterized
subgroups of breast cancer patients. Therefore, we ana-
lyzed the differential expression in primary tumor tissues
of so-called triple-negative breast cancer (TNBC, i.e. es-
trogen, progesteron and Her2 receptor-negative) and
Her2 positive patients by quantitative real-time polymer-
ase chain reaction (qPCR). Isoform-specific Her4 expres-
sion was correlated with the outcome of disease in terms
of event-free and overall survival. Extensive statistical
analysis was applied to evaluate the prognostic value of
Her4 (isoform) expression in well-defined TNBC and
Her2 positive breast cancer cohorts.Methods
TNBC and Her2 positive breast tumor samples
The patients were diagnosed between 1992 and 2008.
Basic patient characteristics are summarized in Table 1.Breast tumor samples and patient characteristics of TNBC
Cryo-preserved tissues (n = 24), as well as formalin-fixed
and paraffin-embedded tissue blocks (n = 52) from 76
female patients with triple-negative breast cancer
derived from the archive of the Institute of Pathology
(University of Regensburg, Germany) were included inthe study. Clinical data were acquired by the Tumor
Center e. V, Regensburg.
The median patient age at diagnosis was 54.3 years,
with a range of 28 to 83 years. A major portion of
patients were diagnosed between 60 and 69.9 years of
age. Another peak of incidence, as is typical for triple-
negative breast cancer, was found in a younger patient
age group i.e. individuals between the ages 40 and
54 years. 97.4% of patients underwent surgery, 61.8% of
them had breast-conserving surgery, 35.5% underwent a
mastectomy. 75.0% of patients were treated with chemo-
therapy. 55.3% of patients received one chemotherapy
regimen, 13.2% had two and 6.6% had three or more
chemotherapy regimes. 8 patients received chemother-
apy in a neoadjuvant setting. Chemotherapeutic regimes
were mainly Taxane- and Antraycline-based. Two pa-
tients were treated with aromatase inhibitor (Anastrozol)
having a hormone receptor-positive second breast car-
cinoma. 35.1% of the patients died and 44.6% suffered
from a recurrence of breast cancer. 4 patients showed
metastasis at the time of primary diagnosis.
Breast tumor samples and patient characteristics of Her2
positive patients
Tissues from 96 female patients were examined regard-
ing their expression of Her4 receptor splice variants. We
Table 2 Her4 isoform-specific primers and probes
JM-a Forward 5′-CCA CCC ATC CCA TCC AAA-3′
Reverse 5′-CCA ATT ACT CCA GCT GCA ATC A-3′
Probe 5′-Fam-ATG GAC GGG CAA TTC CAC TTT ACC
A-Dabcyl-3′
JM-b Forward 5′-CCA CCC ATC CCA TCC AAA-3′
Reverse 5′-CCA ATT ACT CCA GCT GCA ATC A-3′
Probe 5′-Fam-CTC AAG TAT TGA AGA CTG CAT CGG
CCT GAT-Dabcyl-3′
CYT1 Forward 5′-CAA CAT CCC ACC TCC CAT CTA TAC-3′
Reverse 5′-ACA CTC CTT GTT CAG CAG CAA A-3′
Probe 5′-Fam-TGA AAT TGG ACA CAG CCC TCC TCC
TG-Dacyl-3′
CYT2 Forward 5′-CAA CAT CCC ACC TCC CAT CTA TAC-3′
Reverse 5′-ACA CTC CTT GTT CAG CAG CAA A-3′
Probe 5′-Fam-AAT TGA CTC GAA TAG GAA CCA GTT
TGT ATA CCG AGA T-Dabcyl-3
Table 3 β-actin primers and hybridization probes
(Metabion)
β-actin probe (LC Red)
5′-LCRed-610-TGA CCC AGA TCA TGT TTG AGA CCT TCA ACA C-BHQ-2-3′
β-actin Forward1 5′-GGA GCA CCC CGT GCT GC-3′
Reverse1 5′-GCG TAC AGG GAT AGC ACA GCC-3′
β-actin Forward2 5′-CCT GAA CCC CAA GGC CAA CC-3′
Reverse2 5′-GTG GTA CGG CCA GAG GCG-3′
Forward3 5′-ATC TGG CAC CAC ACC TTC TAC AAT-3′
Reverse3 5′-CCG TCA CCG GAG TCC ATC A-3′
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paraffin-embedded specimens. 91 of the 96 patients
(94.8%) underwent surgery as primary therapy, 50
patients (52.1%) received breast-conserving surgery, and
26 patients (27.1%) had a mastectomy. In 20.9% the type
of operational therapy was unknown (n = 20). 80 (83.3%)
patients underwent an adjuvant chemotherapy regimen,
9 patients (6%) received neoadjuvant chemotherapy. 79
patients (82.3%) were treated with trastuzumab. 58 out
of them (60.4%) received trastuzumb at primary diag-
nosis, 17 (17.7%) received trastuzumab upon recurrence
of disease and 4 patients (4%) were treated with trastu-
zumab both times. 13 patients (13.5%) had metastasis at
the time of primary diagnosis.
Control tissue samples
Benign mammary tissue samples (total n = 35, cryo-
preserved n = 13, paraffin-embedded n = 22) were inclu-
ded in the study to compare Her4 expression in tumor
tissues to Her4 expression in non-malignant tissues. This
non-malignant material was identified by a pathologist
and derived from a non-tumorous and separately localized
region of tumor patients’ tissue samples.
RNA isolation, cDNA synthesis and real-time qPCR
RNA isolation of cryo-preserved tissues was performed
using Trizol (peqGOLD TriFast), 70% Isopropanol and
RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. RNA samples were treated
with 10 μl DNase I (Roche Diagnostics, Mannheim,
Germany) to eliminate potential DNA contamination.
The miRNeasy RNA Isolation Kit (Qiagen) was used to
extract RNA from paraffin-embedded tissues. For synthesis
of cDNA a template of 0.5 μg total RNA was used.
According to the manufacturer’s instructions (Transcriptor
First Strand cDNA Synthesis Kit/Roche), the reaction con-
tains random hexamers (Promega, Mannheim, Germany),
reverse transcriptase (Promega), dNTP-mixture and
RNAse inhibitor. To identify false-positive amplification
due to contamination of chromosomal DNA, the reactions
were performed in duplicate in the presence and absence
of reverse transcriptase.
Probes and primers (Metabion, Martinsried, Germany)
for Her4 isoform-specific real-time PCR were synthe-
sized based on the PCR design published by Junttila
et al. [21], (Table 2). The original approach, which was
performed using the Taq-man technology, was trans-
ferred to the Light Cycler (LC) 480 platform (Roche
Diagnostics, Mannheim, Germany). The transfer was
established and validated by e.g. optimizing amplification
efficiencies and verifying amplification specificities.
Real-time PCR was performed using fluorescent
oligonucleotid LC480 hybridization probes (Metabion).
A calibration standard as well as probes and primersannealing to mRNA of β-actin were used as internal
reference and for comparison of successive experiments.
Three different β-actins were used (Table 3) matched to
the length of the splice variants, for an exact com-
parability between target and control in both paraffin-
embedded and cryo-preserved tissues.
A calibration standard comprised of a mixture of
paraffin-embedded cell lines (ZR.75.1, MCF-7, T47D)
expressing the splice variants served as a second internal
control. Every sample was carried out in triplicate.
PCR was carried out in a final volume of 10 μl
containing 2.5 μl cDNA template (1:5 attenuation), 5 μl
LC480 Probes Master (Roche), 1 μl probe and 1.5 μl
primers (0.75 μl primer β-actin, 0.75 μl primer target).
Probes were labeled with fluorescent reporter dyes FAM
(Her4 isoform probes) or LC Red (β-actin probes). Ther-
mal cycling started with the pre-incubation at 95°C for
10 minutes. Then amplification was carried out for 45 -
cycles, initiated with 30 s at 60°C followed by 15 s at 95°C
on a LC480.
For unifying qPCR results derived from the analysis of
cryo-preserved and paraffin-embedded tissues, we
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into account different amplification efficiencies. The
factor was generated by analyzing matched paraffin-
embedded/cryo-preserved tissue samples of the same
patient (n = 26). This systematic comparison revealed a
4.9-fold higher amplification efficiency of RNA derived
from frozen tissues.
Ethical approval
All experiments were approved by the Ethics Committee
of the University of Regensburg (permission no.: 13-101-
0012). All patients included in the experiments provided
written informed consent based on a procedure ap-
proved by the Ethics Committee of the University of
Regensburg (permission no.: 05–176). Overall, all expe-
riments were performed in accordance with relevant
institutional and national guidelines, regulations and
approvals.
Statistical analysis
Categorical data are presented as frequency counts and
percentages, continuous variables as median and range.
To compare Her4 expression levels between different
groups, the non-parametric Mann–Whitney U Test was
used. To analyze the correlation between Her4 isoforms
and clinicopathologic parameters, Spearman’s rank cor-
relation coefficients were calculated.
Event-free survival (EFS) and overall survival (OS)
times were calculated from the date of diagnosis to the
date of event (tumor recurrence or death), respectively.Figure 1 Box Plot diagram showing relative Her4 (JM-a) expression in
irrespective of grading (A) and differentiated in terms of grading 2 an
and median expression levels (M) are indicated”. P-values indicate expressio
log-2 based data displayed on the y-axes.Patients without an event were classified as censored at
the last date to be known event free and alive. To assess
the prognostic value of Her4 (JM-a) expression on EFS
and OS, univariable and multivariable Cox proportional
hazard models were calculated. Variables with p < 0.10 in
a univariable analysis were entered into a multivariable
model. Hazard ratios (HR) and corresponding 95% con-
fidence intervals (CI) were calculated according to the
likelihood ratio test, and a two-sided P value of < 0.05
was considered to indicate statistical significance. All
analyses were performed using IBM SPSS Statistics 20.0
and SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
We performed a Her4 isoform-specific expression ana-
lysis in 76 TNBC and 96 Her2 positive tissues of female
tumor patients. If available, the associated non-
malignant tissues were examined in addition (matched
pair analysis, n = 26).
Her4 isoform expression in TNBC and Her2 positive
patients
We found the Her4 juxtamembrane JM-a splice variants
expressed at a frequency of 18.4% (14 of 76) in triple-
negative and 43% (41 of 96) in Her2 positive breast
cancer samples. The relative expression level of Her4
(JM-a) differs up to 6.9-fold in TNBC tissues and up to
4.1-fold in Her2 positive tissues (Figure 1A).
JM-b receptor variants were not found in any of the
examined breast tissues. JM-a/CYT1 and JM-a/CYT2TNBC, benign tissues, and Her2 positive breast cancer tissues
d grading 3 (B), respectively”. Numbers of specimens analyzed (n)
n levels between compared groups (Mann–Whitney U test). Note the
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CYT1/CYT2 expression ratios vary and range from 0.12
to 11 in TNBC specimens and from 0.38 to 3.77 in Her2
positive tissues.
Her4 (JM-a) expression in non-malignant (control) tissues
Figure 1A: The relative Her4 expression in non-
malignant specimens (n = 34) differs up to 14.3-fold and
is higher than in TNBC (p = 0.005). The Her4 expression
in Her2 positive tissues is only tendentially lower than in
benign tissues (p = 0.64). Figure 2B: Poorly differentiated
(G3), Her2 positive tumors show lower Her4 expressionFigure 2 Kaplan-Meier curves of the effect of Her4 (JM-a) expression
patients (C and D), respectively.levels than middle grade (G2) tumor tissues (p = 0.003).
Poorly differentiated TNBC tissues (G3) have signifi-
cantly lower Her4 expression levels than non-malignant
tissues (p = 0.02).
Her4 (JM-a) expression in TNBC and Her2 positive
patients as a function of tumor grading
Overall the median relative Her4 (JM-a) expression level
was significantly lower in TNBC (p = 0.005) but not in
Her2 positive tumor tissues (p = 0.64) compared to
benign breast tissues (Figure 1A). TNBC samples show
lower Her4 expression levels than Her2 positiveon EFS (A) and OS (B) of TNBC (A and B) and Her2 positive
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respect to grading 2 and 3 showed that Her4 expression
turned out to be expressed at lower levels in poorly
differentiated (G3) tumors compared to moderately
differentiated (G2) Her2 positive tumors (p = 0.003). In
G3-classified TNBC specimens Her4 expression was only
tendentially lower compared to G2 samples (p = 0.22)
(Figure 1B).Her4 dependent analyses of EFS and OS of TNBC and
Her2 positive patients
Her4 (JM-a) positive and negative specimens were
dichotomized based on a PCR expression value < 0.6
and ≥ 0.6, respectively.
In the TNBC samples, univariable Cox regression
analysis showed a significant impact of JM-a expres-
sion on OS (HR = 0.15, 95% CI [0.01; 0.70], p = 0.01)
but not on EFS (HR = 0.55, 95% CI [0.16; 1.40], p = 0.22).
The corresponding Kaplan-Meier survival curves are
presented in Figure 2A and B. Multivariable analysis,
however, shows that patient age affects the OS (HR = 1.04,
95% CI [1.01; 1.08], p = 0.017) and tumor Staging IV
affects both EFS (HR = 12.40, 95% CI [2.82; 52.21],
p < 0.001) and OS (HR = 8.75, 95% CI [1.61; 43.51],
p = 0.007) (Table 4).Table 4 Univariable and multivariable Cox-regression of Her4 (
parameters
Event-free
Prognostic factor HR (95% CI)
TNBC JM-a univariable 0.55 (0.16; 1.40)
JM-a 0.66 (0.19; 2.35)
Age 1.02 (0.99; 1.05)
Staging
I Referent
II 0.94 (0.35; 3.00)
III 3.10 (0.93; 10.86)
IV 12.40 (2.82; 52.21)
Grading (II [ref.] vs. III) 1.30 (0.54; 3.48)
Her2 pos. JM-a univariable 0.41 (0.22; 0.76)
JM-a 0.50 (0.21; 1.14)
Age 1.01 (0.97; 1.04)
Staging
I Referent
II 2.74 (0.91; 11.83)
III 1.57 (0.33; 8.17)
IV 4.84 (1.18; 24.67)
Grading (II [ref.] vs. III) 0.84 (0.37; 1.92)
Univariable parameters with a p-value <0.1 were included in the multivariable analy
HR hazard ratio, CI 95% confidence interval, bold: p-values < 0.05 indicating significaA univariable Cox proportional hazard analysis re-
vealed a significant, favorable impact of Her4 (JM-a)
expression on EFS in Her2 positive patients (HR = 0.41,
95%-CI [0.22; 0.76], p = 0.004) but not on OS (HR = 0.58,
95%-CI [0.29; 1.12], p = 0.105). Figure 2C and D present
the corresponding Kaplan–Meier survival curves of EFS
and OS categorized by Her4 JM-a expression. In a multi-
variable model including the additional covariates age,
staging and grading, only Staging IV appears to signifi-
cantly affect both EFS and OS (Table 4).Her4 dependent analyses of EFS and OS of Her2 positive
patients with respect to ER expression
The Kaplan-Meier analysis of Her2 positive patients
revealed a significant impact of Her4 expression on EFS
(p = 0.027) and OS (p = 0.007) when the cohort is differ-
entiated in terms of ER expression (Figure 3A and B).
Statistically broken down to Her4/ER positive/negative
cohorts (Figure 3C - E), Her4 expression turned out to
be significantly associated with a prolonged EFS in
Her2/ER double-positive patients (p = 0.011; Figure 3C)
but not with a prolonged OS (p = 0.710; Figure 3D). No
benefit from Her4 expression could be identified in
Her2 positive/ER negative patients, either in terms of
EFS (p = 0.370; Figure 3E) or OS (p = 0.120; Figure 3F).JM-a) expression (< 0.6 vs. ≥ 0.6) and clinicopathological
survival (EFS) Overall survival (OS)
p-value HR (95% CI) p-value
0.223 0.15 (0.01; 0.70) 0.010
0.519 0.22 (0.01; 1.14) 0.149
0.145 1.04 (1.01; 1.08) 0.017
- Referent -
0.913 0.72 (0.24; 2.66) 0.585
0.064 3.53 (0.99; 14.00) 0.054
< 0.001 8.75 ( 1.61; 43.51) 0.007
0.576 1.02 (0.41; 2.77) 0.975
0.004 0.58 (0.29; 1.12) 0.105
0.102 1.27 (0.45; 3.77) 0.654
0.646 1.02 (0.97; 1.07) 0.392
- Referent -
0.110 1.58 (0.40; 10.47) 0.564
0.567 1.47 (0.17; 12.43) 0.705
0.036 9.80 (2.05; 71.84) 0.008
0.68 2.24 (0.83; 6.43) 0.115
sis. For the TNBC collective G1 and G2 specimens were grouped together.
nce.
Figure 3 Cumulative Kaplan-Meier curves of the effect of Her4 (JM-a) and ER expression on EFS and OS of Her2 positive patients.
Panels A and B: EFS and OS of Her2 positive Her4/ER subcollectives are shown. Panels C – F: Kaplan-Meier analyses of the effect of differentially
classified Her4 (JM-a) and ER expression on EFS (C and E) and OS (D and F) of Her2 positive patients.
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(CYT1, CYT2) expression to clinicopathologic parameters
We analyzed the correlation (Spearman-Rho) between
Her4 CYT1 and CYT2 expression and also to the clini-
copathological parameters Grading and Staging (Table 5).
This analysis revealed a significant positive correlation of
CYT1 and CYT2 expression (r = 0.605, p < 0.001). More-
over, in Her2 positive tumors CYT1/CYT2 expression isinversely correlated with tumor grading (CYT1: r = −0.316,
p = 0.002; CYT2: r = −0.298, p = 0.003), which is in agree-
ment with the data presented in Figure 1B).
Discussion
The impact of Her4 RTK expression on the course and
outcome of breast cancer disease remains largely un-
clear. A number of findings emerged implying a
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trast, in-vitro and in-vivo studies demonstrated inhibited
tumor cell proliferation by downregulation of Her4
expression or deactivation of Her4 function upon Her4
targeting [22-24]. The retrospective study we present
here reveals for the first time a favorable impact of Her4
expression on the OS of TNBC patients. In addition, we
confirmed previously described indications for a benefi-
cial impact of Her4 in Her2/ER positive patients [16]. A
differential expression of Her4 isoforms does not,
however, play a critical role in the course and outcome
of these breast cancer subgroups.
In a multivariable Cox model with known strong pre-
dictors for OS and EFS such as age, grading and staging,
Her4 expression was, however, no longer significant.
This is not surprising since we were limited by the num-
ber of events in both collectives and the power to detect
a significant effect of Her4 expression against other
strong predictors is too low. Nevertheless we think that
Her4 expression might still have a significant, independ-
ent effect on EFS and OS, which can only be demon-
strated by an analysis of a larger cohort.
Accumulating data derived from preclinical investiga-
tions suggest that the apparent inconsistency regarding
the importance of Her4 expression could be potentially
explained by an ambivalent Her4 function i.e. pro-
apoptotic [25,26] and pro-proliferative [26,27] activity. A
tumor suppressive or oncogenic Her4 receptor activity
might be attributed to receptor isoforms respectively
expressed. Only the JM-a but not the JM-b extracellular
domain is known to be ligand-independently activated
by TACE-induced cleavage [18,22,27,28]. Subsequently,
the intracellular domain (either CYT1- or CYT2-4ICD)
can be cleaved by γ-secretase and differentially triggers
downstream signaling pathways. Once released, the
4ICD differentially triggers downstream signaling path-
ways e.g. by translocation into the nucleus and coacti-
vation of ER-related gene transcription, which in turn
stimulates cell proliferation [2,29]. Alternatively, the
Wwox protein would rather inhibit 4ICD routing into
the nucleus. If not degraded by the ubiquitin ligase Itch,
soluble 4ICD has been shown to interact via its BH3
subdomain with pro-apoptotic proteins (e.g. BAK)Table 5 Non-parametric correlations (Spearman-Rho) of Her4
clinicopathological parameters
CYT1 CY
r p r
TNBC CYT1 - - 0.605
CYT2 0.605 < 0.001 -
Her2 pos. CYT1 - - 0.595
CYT2 0.595 < 0.001 -
r = correlation coefficient, p = p-value, bold: significant correlations i.e. p-value < 0.05followed by increased permeability of mitochondria,
cytochrom-c release, and finally cell death [15,20,25,27].
Although Her4 inherently possesses a potential biva-
lent activity, the expression analysis of this study
suggests a favored evolvement of a tumorsuppressive
activity rather than oncogenic action. This observation is
supported by the finding of reduced Her4 expression in
rather progressive and poorly differentiated breast
tumors as revealed by our data (Figure 1B) and other
studies [4,27]. Moreover, a reactivation of epigenetically
silenced Her4 has been reported to induce apoptosis in
breast cancer cells [30].
In Her2 positive breast cancer tissues we identified
Her4 to be preferentially expressed in ER-positive rather
than in ER negative specimens (Figure 3). This observa-
tion is in agreement with findings previously reported by
Junttila et al. [22] and recently confirmed by Fujiwara
et al. [31]. Obviously, the Her4 receptor develops its
favorable impact primarily in the presence of ER, which
in turn suggests a functional Her4 (4ICD)/ER inter-
action. This consideration is supported by the observa-
tion that the favorable impact of Her4 expression loses
its significance in the Her2 positive/ER negative collect-
ive, both in terms of EFS (p = 0.370) and OS (p = 0.120).
In contrast, the outcome (OS) of TNBC patients, who
are typically ER negative, is significantly better when the
tumor specimens appear Her4 positive (p = 0.030). Tak-
ing these findings together, the evolvement of a
favorable (tumor suppressive) impact of Her4 expression
in Her2/ER double-positive tumor patients is apparently
inconsistent with a pro-proliferative activity that has
been described in-vitro. Moreover, the Her4 receptor
seems to restrain tumor growth even in the absence of
ER expression, as shown for the TNBC collective.
Within the period of observation, only 2 out of 12 Her4
positive TNBC patients suffered from a local recurrence.
Accordingly, the favorable impact of Her4 expression is
more pronounced in terms of OS (p = 0.03) than in
terms of EFS (p = 0.257).
With respect to differential Her4 isoform expression, a
preferred expression of CYT1 over CYT2 (or vice versa)
intracellular domain, or a pronounced effect of high or
low CYT1/CYT2 expression ratios cannot be concludedreceptor isoform expression (CYT1, CYT2) with
T2 Grading Staging
p r p r p
< 0.001 −0.206 0.076 −0.094 0.441
- −0.167 0.152 −0.035 0.774
< 0.001 −0.316 0.002 −0.220 0.051
- −0.298 0.003 −0.033 0.776
.
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http://www.biomedcentral.com/1471-2407/13/437either from our data or other studies [22]. One might
speculate that the functional diversity that has been
attributed to the intracellular domain by pre-clinical
studies [3,32,33], can either not be deduced by a des-
criptive study or does not, in fact, play a relevant role
in-vivo. Instead, the identification of Her4 either by
immunohistochemistry [10-13], fluorescence in-situ hybri-
dization (FISH) [14,16], or qPCR [22] seems to be suffi-
cient for attributing a positive impact on the course/
outcome of breast cancer disease. Since JM-b isoforms are
never expressed and CYT1/CYT2 intracellular domains
are always simultaneously expressed, a diagnostic differen-
tiation of Her4 isoforms is obviously not informative.
Considering a more translational approach, it could be
evaluated to what extent the Her4 receptor represents a
potential target that could be therapeutically utilized in
18% of TNBC and in 43% of Her2 positive breast
cancers. As with ER, which basically represents a favor-
able prognostic marker as well, this hormone receptor is
being very successfully targeted with e.g. tamoxifen or
equivalent chemicals. Preclinical studies have revealed
that anti-Her4 targeting with a newly developed anti-
body Ab1479 attenuates receptor activity and in turn
reduces the formation of proliferative cell colonies
[18,24,34]. Hence, even if the presence of a given bio-
marker (ER, Her4) is strongly correlated with a favorable
outcome of disease, targeting this biomarker might be a
potential beneficial therapeutic strategy.Conclusion
Overall, our study reveals a positive impact of Her4 (JM-a)
expression in triple-negative (OS) and Her2/ER-positive
(EFS) breast cancer. The ever-growing body of evidence
supporting the favorable impact of Her4 expression in
breast cancer suggests the need to reexamine the com-
monly accepted idea that (over-)expression of (receptor)
tyrosine kinases is necessarily associated with oncogenic
activity. Only further extensive functional in-vitro and
in-vivo analyses focusing on the importance of Her4 in the
context of differential Her receptor co-expression will
facilitate the consideration of this important receptor in
individually optimized therapy based on a modular
approach [35].Abbreviations
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